E. David Crawford, MD, Editor-in-Chief
LEARNING CENTERS
LATEST CONTENT
Sanjay G. Patel, MD, reviews some of the more salient updates pertaining to prostate cancer discussed at the American Urological Association’s 2019 Annual Meeting. He covers the following topics: reducing persistent opioid use following radical prostatectomy, results from a pivotal trial of an MRI-guided transurethral ultrasound ablation (TULSA) device, BRCA germline testing, findings from the CALGB 90601 trial, and molecular imaging for patients with biochemical recurrence.
Christopher P. Smith, MD, MBA, MSS, reviews management recommendations from the 6th International Consultation on Incontinence guidelines, as well as recent literature on the treatment of male stress urinary incontinence. He discusses treatment approaches, including urethral bulking agents, male slings, artificial urinary sphincter, and adjustable balloons.
Christopher P. Smith, MD, MBA, MSS, describes the treatment pathway for advanced overactive bladder (OAB) patients as described in the American Urological Association (AUA)/ Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU) OAB guidelines. He discusses novel treatment approaches, including rechargeable sacral neuromodulation devices, implantable tibial nerve stimulators, bladder denervation, and transcutaneous stimulation of the tibial nerves.
Thomas J. Polascik, MD, FACS, surveys the current status of germline testing for prostate cancer in screening populations, and explains how his institution, Duke University, has been advancing research in this area. He discusses current studies measuring the ability of germline testing to predict outcomes, highlights the Duke algorithm for when and whom to test, and describes challenges for integrating germline testing into the current model of prostate cancer screening.
PCa Commentary | Volume 140 - November 2019 Posted by Edward Weber | November 2019 Role of Androgen Suppression Added to Salvage Radiotherapy Following Prostatectomy for High-Risk Prostate Cancer: In Selected Cases, No Benefit and Associated Harm Adjuvant...
Fred Saad, MD, FRCS, presents findings from an exploratory analysis he led and presented at the American Urological Association’s 2019 Annual Meeting. The study evaluated the association between DECIPHER genomic classifier (GC) score and metastasis-free survival following apalutamide treatment in nonmetastatic castrate-resistant prostate cancer (nmCRPC) patients included in the SPARTAN study.
Michael A. Brooks, MD; A. Edward Yen, MD; Richard E. Link, MD, PhD; and Wesley A. Mayer, MD, an interdisciplinary panel of kidney cancer experts, present representative cases of renal cell carcinoma in order to discuss current management controversies. The session reviews data supporting management recommendations, surgical approaches for small renal masses, lymphadenectomy, adjuvant therapy, and cytoreductive nephrectomy and partial nephrectomy.
